|
PPIG expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.88498130835069E-15 |
| Normal-vs-Stage2 |
7.72080177569023E-11 |
| Normal-vs-Stage3 |
4.55191440096314E-15 |
| Normal-vs-Stage4 |
7.08977321295379E-12 |
| Stage1-vs-Stage2 |
1.268630E-01 |
| Stage1-vs-Stage3 |
8.381900E-02 |
| Stage1-vs-Stage4 |
1.948040E-01 |
| Stage2-vs-Stage3 |
8.075800E-01 |
| Stage2-vs-Stage4 |
8.079200E-01 |
| Stage3-vs-Stage4 |
9.772600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.66780000002242E-06 |
| Normal-vs-Asian |
7.629900045103E-09 |
| Caucasian-vs-AfricanAmerican |
6.732200E-01 |
| Caucasian-vs-Asian |
7.449800E-01 |
| AfricanAmerican-vs-Asian |
8.830200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62492241884138E-12 |
| Male-vs-Female |
8.352300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.78246306603569E-12 |
| Normal-vs-Age(41-60Yrs) |
3.33066907387547E-16 |
| Normal-vs-Age(61-80Yrs) |
1.63569158218024E-12 |
| Normal-vs-Age(81-100Yrs) |
2.31679999999068E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.534420E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.498200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.425600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.769400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.043800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.860400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.201400E-01 |
| Classical-VS-Follicular |
6.481700E-02 |
| Classical-VS-Other |
4.735000E-01 |
| Classical-VS-Normal |
1.62503344114384E-12 |
| Tall-VS-Follicular |
8.399000E-01 |
| Tall-VS-Other |
9.275600E-01 |
| Tall-VS-Normal |
6.12329964511105E-10 |
| Follicular-VS-Other |
9.843200E-01 |
| Follicular-VS-Normal |
8.61677396102323E-12 |
| Other-VS-Normal |
7.843100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
4.95999996630303E-09 |
| N0-vs-N1 |
3.596400E-01 |
|
|
